[go: up one dir, main page]

FR08C0036I2 - - Google Patents

Info

Publication number
FR08C0036I2
FR08C0036I2 FR08C0036C FR08C0036C FR08C0036I2 FR 08C0036 I2 FR08C0036 I2 FR 08C0036I2 FR 08C0036 C FR08C0036 C FR 08C0036C FR 08C0036 C FR08C0036 C FR 08C0036C FR 08C0036 I2 FR08C0036 I2 FR 08C0036I2
Authority
FR
France
Prior art keywords
disease
sarcoma
treating
telangienctasia
osler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0036C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Cor
Original Assignee
Childrens Medical Center Cor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Center Cor filed Critical Childrens Medical Center Cor
Publication of FR08C0036I1 publication Critical patent/FR08C0036I1/fr
Application granted granted Critical
Publication of FR08C0036I2 publication Critical patent/FR08C0036I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Thalidomide for treating solid and blood-borne tumours, wherein said tumour is a breast cancer, leukaemia, neoplastic disease of the bone marrow, Kaposi's sarcoma, hemangioma, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, osteosarcoma, acoustic neuroma, neurofibroma, trachoma, or pyogenic granuloma;and for treating ocular neovascular disease, macular degeneration, proliferative vitreoretinopathy, retrolental fibroplasia, psoriasis, Crohn's disease, diabetic retinopathy, Osler-Weber-Rendu disease, hereditary hemorrhagic telangienctasia or osteoarthritis.
FR08C0036C 1993-03-01 2008-08-01 Active FR08C0036I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2504693A 1993-03-01 1993-03-01
US08/168,817 US5629327A (en) 1993-03-01 1993-12-15 Methods and compositions for inhibition of angiogenesis
PCT/US1994/001971 WO1994020085A1 (en) 1993-03-01 1994-02-24 Methods and compositions for inhibition of angiogenesis

Publications (2)

Publication Number Publication Date
FR08C0036I1 FR08C0036I1 (en) 2008-10-17
FR08C0036I2 true FR08C0036I2 (en) 2009-11-20

Family

ID=26699202

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0036C Active FR08C0036I2 (en) 1993-03-01 2008-08-01

Country Status (19)

Country Link
US (18) US5629327A (en)
EP (4) EP1264597B1 (en)
JP (4) JPH08507767A (en)
KR (1) KR100506043B1 (en)
AT (2) ATE218865T1 (en)
AU (1) AU676722B2 (en)
BR (1) BR9400764A (en)
CA (3) CA2342974C (en)
CO (1) CO4230017A1 (en)
DE (3) DE69434490T2 (en)
DK (2) DK1264597T3 (en)
ES (2) ES2174873T3 (en)
FR (1) FR08C0036I2 (en)
LU (1) LU91471I2 (en)
NL (1) NL300358I2 (en)
NZ (4) NZ336527A (en)
PE (1) PE10095A1 (en)
PT (1) PT688211E (en)
WO (1) WO1994020085A1 (en)

Families Citing this family (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) * 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6805865B1 (en) 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
DE4422237A1 (en) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Use of lactam compounds as active pharmaceutical ingredients
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
JP3263598B2 (en) * 1995-11-01 2002-03-04 有限会社ドット Bioactive peptide composition for nasal absorption
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ATE530542T1 (en) * 1996-07-24 2011-11-15 Celgene Corp AMINO SUBSTITUTED 2-(2,6-DIOXOPIPERIDINE-3-YL)-PHTHALIMIDE TO REDUCE TNF-ALPHA LEVELS
EP2859895A1 (en) * 1996-07-24 2015-04-15 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
DK1920773T3 (en) * 1996-11-05 2011-03-28 Childrens Medical Center Thalidomide and dexamethasone for the treatment of tumors
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
US6265388B1 (en) 1997-03-21 2001-07-24 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
US6174695B1 (en) 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
JP2001513559A (en) 1997-08-25 2001-09-04 ブレム，ハロルド Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
ES2192342T3 (en) * 1997-11-18 2003-10-01 Celgene Corp 2- (2,6-DIOXO-3-FLUOROPIPERIDIN-3-IL) -ISOINDOLINAS REPLACED AND ITS USE TO REDUCE TNFALFA LEVELS.
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
BR9908811A (en) * 1998-03-16 2000-12-05 Celgene Corp Compound, pharmaceutical composition and its use in the treatment of mammals
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6482802B1 (en) 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
AU749356B2 (en) * 1998-05-11 2002-06-27 Children's Medical Center Corporation Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8609614B2 (en) 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
WO2000017197A1 (en) * 1998-09-21 2000-03-30 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6596690B2 (en) 1998-10-06 2003-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
FR2784580B1 (en) 1998-10-16 2004-06-25 Biosepra Inc POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2000041547A2 (en) * 1999-01-13 2000-07-20 The Rockefeller University Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
ATE306469T1 (en) * 1999-03-18 2005-10-15 Celgene Corp SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR LOWERING THE LEVELS OF INFLAMMATORY CYTOKINE
SI1040838T1 (en) 1999-03-31 2003-08-31 Gruenenthal Gmbh Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6673843B2 (en) 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6916843B1 (en) * 1999-08-11 2005-07-12 The United States Of America As Represented By The Department Of Health And Human Services Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
ES2356369T3 (en) 1999-11-10 2011-04-07 Biopheresis Technologies, Inc. METHOD AND SYSTEM OF ELIMINATING THE CYTOKIN INHIBITOR IN PATIENTS.
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
CA2387805C (en) 1999-11-18 2012-08-28 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
AU4515001A (en) * 1999-12-02 2001-06-18 Regents Of The University Of Michigan, The Compositions and methods for locally treating inflammatory diseases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CN1121218C (en) * 2000-03-08 2003-09-17 台湾东洋药品工业股份有限公司 Application of thalidomide in pharmaceutical composition for treating hepatocellular carcinoma
EP2286799B1 (en) 2000-03-24 2015-07-29 Biosphere Medical, Inc. Microspheres for active embolization
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
AU2001249755A1 (en) * 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
DE60118547T2 (en) * 2000-05-15 2007-02-01 Celgene Corp. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLORECTAL CANCER CONTAINING THALIDOMIDE AND IRINOTECANE
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) * 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US20040121945A1 (en) * 2000-12-15 2004-06-24 Hong Liang Compositions and methods for inhibiting endothelial cell proliferation
EP1226824A1 (en) * 2001-01-24 2002-07-31 TTY Biopharm Company Limited Use of thalidomide for the treatment of hepatocellular carcinoma
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
ATE450529T1 (en) * 2001-02-27 2009-12-15 Governement Of The United Stat ANALOGUE OF THALIDOMIDE AS ANGIOGENESIS INHIBITORS
CA2444704C (en) * 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
WO2003012122A2 (en) * 2001-07-27 2003-02-13 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer
ES2325916T3 (en) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation ANTIANGIOGENIC ACTIVITY OF TALIDOMIDE ANALOGS REPLACED WITH NITROGEN.
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
ES2431040T3 (en) * 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of Slit and Roundabout-mediated angiogenesis (Robo), and their uses
AU2003220091B2 (en) * 2002-03-08 2006-02-16 Emory University Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
EP1496916A2 (en) * 2002-04-09 2005-01-19 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
EP2915533B1 (en) 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CN1668296A (en) 2002-05-17 2005-09-14 细胞基因公司 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2004002418A2 (en) * 2002-06-26 2004-01-08 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
PT2269656E (en) 2002-07-15 2014-12-02 Univ Texas Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer
AU2003254120B2 (en) * 2002-07-22 2009-09-10 Teva Pharamceuticals International Gmbh Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
EA008683B1 (en) * 2002-07-23 2007-06-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
CA2501936A1 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2505131A1 (en) 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
JP2006512318A (en) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド Histone deacetylase inhibitors for treating ocular neovascularization or edema-like diseases and disorders
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) * 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
WO2008109433A2 (en) 2007-03-02 2008-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
DE10323898A1 (en) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
CA2527074A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
AR042955A1 (en) 2003-07-18 2005-07-13 Amgen Inc UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
JP4943845B2 (en) 2003-09-17 2012-05-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Thalidomide analog
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
AU2003286931A1 (en) * 2003-11-06 2004-06-06 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
ZA200603718B (en) 2003-11-06 2007-09-26 Celgene Corp Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
BRPI0417186A (en) * 2003-12-02 2007-03-06 Celgene Corp method of treating an individual having a hemoglobinopathy or anemia, modulating the differentiation of a cd34 + stem cell or precursor into an erythroid lineage, and, pharmaceutical composition
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US7430276B2 (en) * 2004-02-25 2008-09-30 Nanodynamics-88 Low dose X-ray mammography method
US7498322B2 (en) * 2004-03-12 2009-03-03 Entremed, Inc. Antiangiogenic agents
NZ550026A (en) * 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes
MXPA06011798A (en) * 2004-04-14 2007-01-16 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes.
JP2007533759A (en) * 2004-04-23 2007-11-22 セルジーン・コーポレーション Composition comprising thalidomide for treatment and management of pulmonary hypertension and method of use thereof
KR20070010184A (en) * 2004-04-23 2007-01-22 셀진 코포레이션 Methods of using immunomodulatory compounds for the treatment and management of pulmonary hypertension and compositions comprising the compounds
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
US7273890B1 (en) * 2004-06-08 2007-09-25 Sagittarius Life Science Corp. ST104P, an anti-angiogenic agent
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
KR20070057907A (en) * 2004-09-03 2007-06-07 셀진 코포레이션 Method for preparing substituted 2- (2,6-dioxopiperidin-3-yl) -1-oxoisoindolin
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
CA2588597A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
EP2484344B1 (en) 2005-05-09 2016-02-10 Biosphere Medical, S.A. Compositions and methods of using microspheres and non-ionic contrast agents
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20080167272A1 (en) * 2005-06-16 2008-07-10 Auckland Uniservices Limited Thalidomide metabolites and methods of use
DK2380887T3 (en) * 2005-06-30 2013-10-07 Celgene Corp METHODS FOR PREPARING 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION COMPOUNDS
US20080279912A1 (en) * 2005-07-12 2008-11-13 Regents Of The University Of California Office Of Technology Transfer Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CN1939922B (en) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
KR20080055914A (en) * 2005-10-14 2008-06-19 에프. 호프만-라 로슈 아게 Administration regimen of 5- (2-chlorophenyl) -1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3,4-k] [1,4] benzodiazepine
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP1986706B1 (en) * 2006-01-30 2011-08-17 Biosphere Medical, Inc. Porous intravascular embolization particles and methods of making them
US20080033366A1 (en) * 2006-01-30 2008-02-07 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
AU2007227256B2 (en) * 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20070226632A1 (en) * 2006-03-21 2007-09-27 Nokia Corporation Method, electronic device and computer program product for enhancing contact list functionality
WO2007120669A1 (en) * 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
ZA200809956B (en) * 2006-05-26 2010-07-28 Celgene Corp Methods and compositions using Immunomodulatory compounds in combination therapy
US20080051431A1 (en) * 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (en) 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
WO2008011513A2 (en) 2006-07-19 2008-01-24 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
CL2007002218A1 (en) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA.
CN101138634A (en) * 2006-09-07 2008-03-12 于保法 Composition for treating tumour
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
US20090068236A1 (en) * 2007-04-13 2009-03-12 Chemgenex Pharmaceuticals, Inc. Oral Cephalotaxine Dosage Forms
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CN101802008B (en) 2007-08-21 2015-04-01 安美基公司 Human C-FMS antigen binding proteins
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2203161B1 (en) * 2007-09-26 2018-05-09 Indiana University Research and Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
JP5809415B2 (en) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド Compositions and methods of anti-VEGF antibodies
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
CN102143996A (en) * 2008-10-30 2011-08-03 大卫·刘 Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
GB0914330D0 (en) 2009-08-17 2009-09-30 Univ Dublin City A method of predicting response to thalidomide in multiple myeloma patients
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012079088A2 (en) 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
CN103703000B (en) 2011-03-23 2015-11-25 安姆根有限公司 The fused tricyclic double inhibitor of CDK4/6 and FLT3
CN103688176A (en) 2011-04-29 2014-03-26 细胞基因公司 Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
EP2817300B1 (en) 2012-02-21 2018-04-25 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
CA3136093C (en) * 2012-06-29 2025-07-08 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
DK2956183T3 (en) 2013-02-13 2021-06-14 Cartiheal 2009 Ltd FIXED SUBSTRATES FOR PROMOTING CELL AND TISSUE GROWTH
HK1220205A1 (en) 2013-03-15 2017-04-28 Celgene Corporation Modified t lymphocytes
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015116802A1 (en) 2014-01-29 2015-08-06 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
ES2946179T3 (en) 2014-05-28 2023-07-13 Onco Tracker Inc Antineoplastic effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
PT3182996T (en) 2014-08-22 2023-03-21 Celgene Corp METHODS OF TREATMENT OF MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES
PL3214081T3 (en) 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
AU2015353539A1 (en) 2014-11-26 2017-07-13 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US10001483B2 (en) 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
MX2018000999A (en) 2015-07-24 2018-11-09 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction.
CA3000661C (en) 2015-09-30 2024-04-02 Nigel H. Greig Thalidomide analogs and methods of use
PL3365334T3 (en) 2015-10-21 2024-11-25 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
ES2898329T3 (en) 2016-01-12 2022-03-07 Oncotracker Inc Improved methods for monitoring the immune status of a subject
BR112018069732A2 (en) * 2016-03-31 2019-02-05 Omeros Corporation methods for preventing, treating, reversing and / or delaying angiogenesis in a mammalian subject, for treating a subject suffering from ocular angiogenic disease or condition and for inhibiting tumor angiogenesis
AU2017368332A1 (en) 2016-12-03 2019-06-13 Juno Therapeutics, Inc. Methods for modulation of CAR-T cells
MA46963A (en) 2016-12-03 2019-10-09 Juno Therapeutics Inc METHODS FOR DETERMINING THE DOSAGE OF CAR-T CELLS
SI3558955T1 (en) 2016-12-22 2021-12-31 Amgen Inc., Benzisothiazole, isothiazole (3,4-b) pyridine, quinazoline, phthalazine, pyrido (2,3-d) pyridazine and pyrido (2,3-D) pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung cancer, pancreatic cancer or colorectal cancer
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
DK3618842T3 (en) 2017-05-01 2024-01-02 Juno Therapeutics Inc COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATING COMPOUND
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
KR20200074997A (en) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 Antibodies and chimeric antigen receptors specific for B-cell maturation antigens
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN112204048A (en) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 Anti-CCT5 binding molecules and methods of use
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019210080A1 (en) * 2018-04-25 2019-10-31 The Regents Of The University Of California Methods and compositions for skeletal and neurological disorders
MA52496A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
JP7266043B2 (en) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using them
MA52564A (en) 2018-05-10 2021-03-17 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
MA52765A (en) 2018-06-01 2021-04-14 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA51848A (en) 2018-06-12 2021-04-21 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
AU2019377854A1 (en) 2018-11-08 2021-05-27 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
KR20210104713A (en) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Engineered T-cell dosing methods for treatment of B-cell malignancies
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
EP3883565A1 (en) 2018-11-19 2021-09-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc KIF18A inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
KR20210146288A (en) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. Bicyclic heterocyclyl compounds and uses thereof
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
JP7092935B2 (en) 2019-05-21 2022-06-28 アムジエン・インコーポレーテツド Solid form
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
MX2022001302A (en) 2019-08-02 2022-03-02 Amgen Inc KIF18A INHIBITORS.
JP7640521B2 (en) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Heteroaryl amides useful as KIF18A inhibitors - Patents.com
MX2022004656A (en) 2019-10-24 2022-05-25 Amgen Inc PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF KRAS G12C AND KRAS G12D IN THE TREATMENT OF CANCER.
BR112022008535A2 (en) 2019-11-04 2022-08-09 Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT CANCER AND A RAS PROTEIN DISORDER
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
BR112022008858A2 (en) 2019-11-08 2022-09-06 Revolution Medicines Inc COMPOUND, PHARMACEUTICAL COMPOSITION AND METHODS FOR INHIBITING SOS1 IN A SUBJECT, FOR INHIBITING THE INTERACTION OF SOS1 AND A PROTEIN, TO TREAT OR PREVENT A DISEASE AND TO TREAT OR PREVENT CANCER
MX2022005708A (en) 2019-11-14 2022-06-08 Amgen Inc IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND.
TW202132271A (en) 2019-11-14 2021-09-01 美商安進公司 Improved synthesis of kras g12c inhibitor compound
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
IL294484A (en) 2020-01-07 2022-09-01 Revolution Medicines Inc Dosage for shp2 inhibitor and methods for treating cancer
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc Ras inhibitors
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
MX2024010828A (en) 2022-03-07 2024-09-17 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carboni trile.
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Methods for treating immune-refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250029137A (en) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Treatment methods for second-line therapy with CD19-targeted CAR T cells
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
TW202504611A (en) 2023-03-30 2025-02-01 美商銳新醫藥公司 Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN121100123A (en) 2023-04-14 2025-12-09 锐新医药公司 Crystalline form of Ras inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) * 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US3142672A (en) * 1957-09-03 1964-07-28 Takeda Pharmaceutical Derivatives of nu-alpha-phenyl-and nu-alpha-biphenylylbutyric acids and amino sugars
US3560495A (en) * 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US3563986A (en) * 1965-10-12 1971-02-16 Ernst Frankus 4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6
DE1670551B2 (en) * 1965-10-30 1973-01-25 SALT TRISUBSTITUTED S-TRIAZINE
AT278739B (en) * 1966-11-08 1970-02-10 Kwizda Fa F Johann Process for the preparation of new anhydrides and imides of substituted dicarboxylic acids
US3705162A (en) * 1967-07-01 1972-12-05 Gruenenthal Chemie 4-phthalimidine glutarimides
US4552888A (en) * 1982-01-15 1985-11-12 Eli Lilly And Company Ascorbic acid ethers in angiogene
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
JP2544136B2 (en) * 1986-05-23 1996-10-16 第一製薬株式会社 Angiogenesis inhibitor and antitumor agent containing sulfated polysaccharide DS4152
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
DE68910138T2 (en) * 1988-01-19 1994-04-28 Childrens Medical Center Fumagillin as an angiostatic agent.
AT393221B (en) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh AGENT WITH DESTROYING EFFECT ON MALIGNE TUMORS, METHOD FOR THE PRODUCTION THEREOF AND PREPARATION FOR USE IN THE THERAPY OF CANCER DISEASES
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
CA1329771C (en) * 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent
US5049154A (en) * 1989-08-07 1991-09-17 Berkshire Research & Development, Inc. Adjustable intra-luminal valvulotome
JPH03109324A (en) * 1989-09-22 1991-05-09 Microbial Chem Res Found Vascularization inhibitor
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5405851A (en) * 1990-06-19 1995-04-11 Burroughs Wellcome Co. Pharmaceutical compounds
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU661299B2 (en) * 1991-04-17 1995-07-20 Grunenthal Gmbh New thalidomide derivatives, method of manufacture and use thereof in medicaments
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
DE4320157A1 (en) 1993-06-18 1994-12-22 Bayer Ag Use of 1,2,4-dithiazolium salts as chemotherapeutic agents
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
AU7376494A (en) 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5405855A (en) 1993-12-23 1995-04-11 Andrulis Pharmaceuticals Corp. Treatment of insulin resistant diabetes with thalidomine
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
EP0761229B1 (en) 1995-03-17 2004-08-04 Toray Industries, Inc. Corneal vascularization inhibitor
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
ATE306469T1 (en) 1999-03-18 2005-10-15 Celgene Corp SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR LOWERING THE LEVELS OF INFLAMMATORY CYTOKINE

Also Published As

Publication number Publication date
US6071948A (en) 2000-06-06
NZ535671A (en) 2006-05-26
EP1264597A3 (en) 2003-03-19
EP1264597A2 (en) 2002-12-11
ATE218865T1 (en) 2002-06-15
CA2157288C (en) 2005-11-08
NZ535670A (en) 2006-05-26
US5712291A (en) 1998-01-27
CA2512926A1 (en) 1994-09-15
JP2004359693A (en) 2004-12-24
US20020161024A1 (en) 2002-10-31
DE69430796T2 (en) 2003-01-30
AU676722C (en) 1994-09-26
EP0688211B1 (en) 2002-06-12
US6977268B2 (en) 2005-12-20
US20020049231A1 (en) 2002-04-25
FR08C0036I1 (en) 2008-10-17
HK1052865A1 (en) 2003-10-03
US20010056113A1 (en) 2001-12-27
JPH08507767A (en) 1996-08-20
LU91471I2 (en) 2008-11-06
US8012996B2 (en) 2011-09-06
PE10095A1 (en) 1995-04-25
US20030176463A1 (en) 2003-09-18
EP1245229A2 (en) 2002-10-02
US20030187024A1 (en) 2003-10-02
US20020119956A1 (en) 2002-08-29
EP1537870A2 (en) 2005-06-08
CA2342974C (en) 2005-08-16
JP2008088182A (en) 2008-04-17
CA2512926C (en) 2010-08-03
DE122008000044I2 (en) 2010-12-30
US20020052398A1 (en) 2002-05-02
US5629327A (en) 1997-05-13
DE122008000044I1 (en) 2009-01-02
CA2157288A1 (en) 1994-09-15
NZ262676A (en) 1999-08-30
ES2174873T3 (en) 2002-11-16
AU676722B2 (en) 1997-03-20
EP1537870A3 (en) 2007-12-12
US20070021464A1 (en) 2007-01-25
CO4230017A1 (en) 1995-10-19
ATE304356T1 (en) 2005-09-15
KR960701632A (en) 1996-03-28
KR100506043B1 (en) 2005-11-08
DE69434490T2 (en) 2006-06-22
DE69434490D1 (en) 2005-10-20
BR9400764A (en) 1994-11-01
CA2342974A1 (en) 1994-09-15
DK0688211T3 (en) 2002-09-23
JP2001278789A (en) 2001-10-10
AU6248694A (en) 1994-09-26
US7723361B2 (en) 2010-05-25
US6235756B1 (en) 2001-05-22
PT688211E (en) 2002-11-29
EP0688211A4 (en) 1997-05-21
NL300358I2 (en) 2009-06-02
WO1994020085A1 (en) 1994-09-15
EP0688211A1 (en) 1995-12-27
US6469045B1 (en) 2002-10-22
EP1264597B1 (en) 2005-09-14
NZ336527A (en) 2005-01-28
EP1245229A3 (en) 2004-05-06
ES2245711T3 (en) 2006-01-16
US20050215593A1 (en) 2005-09-29
DE69430796D1 (en) 2002-07-18
NL300358I1 (en) 2008-11-03
US5593990A (en) 1997-01-14
US20020061911A1 (en) 2002-05-23
DK1264597T3 (en) 2006-01-16
JP4065373B2 (en) 2008-03-26
US20020061923A1 (en) 2002-05-23
US6420414B1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
FR08C0036I2 (en)
AU642867B2 (en) Treatment of fabric with perfume/cyclodextrin complexes
EP1020522A4 (en) Natural human antibody
GB9503601D0 (en) Method of treatment and method of manufacture of medicament
HU911968D0 (en) Process for the production of medical preparations containing modalphynyl
ZA936492B (en) Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
ZA965686B (en) Cascade polymer complexes process for their production and pharmaceutical agents containing said complexes
EE04752B1 (en) Monoclonal antibody, hybridoma producing it and use of antibody
HUP9904092A3 (en) Pharmaceutical composition for treatment hiv and cancer and process for producing it
EP0552296A4 (en) Mouse monoclonal antibodies
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
AU633867B2 (en) Delivery of cytotoxic agents
ATE254481T1 (en) RADIOACTIVE CHITOSAN COMPLEX AND ITS APPLICATION IN RADIATION THERAPY
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
RU95120677A (en) METHOD FOR TREATING MALIGNANT TUMORS
GB9625193D0 (en) Treatment of highly vascular tumours
FR2707288B1 (en) Tertiary butylaminoethyl methacrylate chloride, process for its preparation and its applications.
FR2700337B1 (en) Imidazopyridine-2-one derivatives, their preparation process and their use in therapy.
FR2696548B1 (en) X-ray source, process for producing this source and application to diffractometers.
ES2118758T3 (en) COMPOSITIONS AND METHOD FOR SOFT TISSUE TUMORS.
BG50534A1 (en) Method for the radio protection of biological objects under fractional and prolonged irradiation conditions